Biologically-Adapted, Dose-Escalated Radiotherapy for the Treatment of Ewing Sarcoma, BEAR Trial

Shown exactly as written on ClinicalTrials.gov. Your oncologist is the right person to judge whether it fits your situation.

Inclusion Criteria:

* Histological confirmation of Ewing sarcoma, including both skeletal and extra-skeletal primary tumors. Patients with "Ewing-like" sarcoma may be eligible if patients are planned to be treated per Ewing treatment paradigms, as defined in this clinical trial
* Patients of age ≥ 2 years are eligible for the study
* Lansky or Karnofsky performance status ≥ 70
* Ability to provide written informed consent and complete questionnaire(s) by themselves or with assistance
* Willing to provide blood samples for correlative research purposes
* Willing to provide biopsy sample to run Mayo Complete Solid Tumor Panel if tumor size is \>= 8 cm

Exclusion Criteria:

* Prior chemotherapy or radiotherapy that, in the opinion of the treating medical oncologist or radiation oncologist, is considered to interfere with the current treatment or measurement of outcomes
* Receiving any investigational agent which would be considered as a treatment for the primary neoplasm that is considered by the investigator to interfere with the current treatment or measurement of outcomes

  * Note: Co-enrollment on another clinical trial is allowed per the treating radiation oncologist's discretion
* Other active malignancy ≤ 1 year prior to registration that is considered by the investigator to interfere with the current treatment or measurement of outcomes
* Patients that have severe co-morbid systemic illness or other disease which would interfere significantly with the current treatment or measurement of outcomes
* Patients that have active uncontrolled systemic infection, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, or psychiatric illness or social situation that would limit study adherence
* Any of the following:

  * Pregnant patients
  * Nursing patients